archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited and National Blood Authority sign new Australian Fractionation Agreement
    2009 CSL Limited ASX CSL announced today that it has signed an agreement with the National Blood Authority acting on behalf of both State and Commonwealth Governments to continue to provide the Australian community with safe secure and affordable plasma therapeutic products CSL welcomes the opportunity to continue our longstanding commitment to provide plasma derived therapeutic products for use by Australians living with serious medical conditions Managing Director and Chief

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255923013047/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL Organisational Changes
    biopharmaceutical company announced today a number of changes in its organisation structure and its senior executive group within the context that Dr Brian McNamee would be continuing as CEO and Managing Director for at least a further three to four years Following a period of outstanding leadership Mr Peter Turner will become Chief Operating Officer CSL Group effective 1 January 2010 and will join the CSL Board as an Executive

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255922886431/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Full-year Results for 2008/09
    Home Archived ASX Releases Full year results for 2008 09 Full year results for 2008 09 Melbourne Australia 19 08 2009 CSL Limited today announced a profit after tax of 1 15 billion for the twelve months ended 30 June 2009 up 63 when compared to the twelve months ended 30 June 2008 Underlying operational profit adjusted for currency movements the impact of discontinuing the Talecris merger and non operational

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1249870447081/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Accounting treatment – conversion of USD$1.5 billion funds on deposit to Australian dollars
    Contact CSL Home Archived ASX Releases Accounting treatment conversion of USD 1 5 billion funds on deposit to Australian dollars Accounting treatment conversion of USD 1 5 billion funds on deposit to Australian dollars Melbourne Australia 22 06 2009 On 9 June 2009 CSL Limited ASX CSL made an announcement to the Australian Securities Exchange regarding the termination of the Talecris Biotherapieutics merger agreement During the subsequent media and market briefing Listen to the recording made during the analyst briefing the company referred to an approximate AUD 150 million foreign exchange benefit arising from selling forward into Australian dollars approximately USD 1 5 billion held on deposit in anticipation of acquiring Talecris Biotherapeutics At the time the company indicated this amount was a cash benefit only Following audit advice this foreign exchange benefit will now be reflected in the Group s Income Statement Profit Loss statement for the period ending 30 June 2009 This transaction will result in a non recurring net profit after tax benefit of approximately AUD 150 million After taking into consideration the previously disclosed transaction break fee and other termination costs the net financial impact is a non recurring net profit after tax of approximately AUD

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1244834434392/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Recording of June 9, 2009 Analyst Briefing
    Officer Dr Brian McNamee This was recorded on June 9th 2009 following the announcement that CSL and Talecris Biotherapeutics have agreed to terminate the merger agreement CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement 0 1Mb Listen Now This recording is approximately 30 minutes long and can be listened to stopped and restarted using the controls below Media Contacts Australia Dr Rachel David Director Public Affairs CSL Limited Telephone

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242704012355/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL and Talecris Agree to Terminate Merger
    we have previously stated we fundamentally disagree with the FTC case and matters included in their complaint Although we continue to believe in the many customer benefits and significant financial synergies that supported the transaction CSL s Board of Directors did not believe that entering into a protracted litigation process with the FTC with its inherent risks substantial costs and lengthy distraction of CSL management and staff from planning and running our businesses would be in the best interests of our stakeholders Dr McNamee continued While we regret that the transaction cannot be completed CSL remains a well positioned global biopharmaceutical business and will continue to expand on its core strengths We have consistently produced yearon year growth for our shareholders and we are confident in the continued value and growth potential of our stand alone business We continue to have great respect for Talecris and wish them well in the future Lawrence D Stern Talecris Chairman and Chief Executive Officer said After discussions with CSL we have mutually agreed that litigation regarding the antitrust issue was not the path forward Based on a careful analysis of the situation and all alternatives available we believe that termination of the merger agreement is in the best interest of all parties We are disappointed that patients will not benefit from the efficiencies we saw in the proposed combination Talecris continues to focus on its patient community and customers and on building and realizing value for its employees and owners Through the process we developed an even greater appreciation for CSL s competencies professionalism and integrity and we wish Brian and his team well in their future endeavors Both parties will fulfil their obligations for termination contained in the merger agreement As part of the agreement CSL will pay Talecris a US 75

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703994967/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL announces on-market share buyback
    Limited ASX CSL today announced its intention to conduct an on market share buyback of up to 54 863 000 shares 1 This represents approximately 9 of the company s current shares on issue At an assumed price per share of approximately A 29 being CSL s last closing price on Friday 5 June this would represent a total buy back consideration of up to A 1 59 billion Dr McNamee CSL s Managing Director said Last year investors supported CSL with its Talecris acquisition plan by participating in the equity raising Given the company will no longer be acquiring Talecris we think it appropriate for funds to be returned to shareholders The buyback will improve investment return ratios such as earnings per share and return on equity to the benefit of shareholders We are committed to managing the company s capital structure in the interests of our shareholders Given the Company s strong cash flows and balance sheet position CSL is expected to retain a prudent level of gearing following the buyback Shares will be purchased on market during the twelve month period commencing 23 June 2009 2 Download this release CSL announces on market share buyback 0 08MB

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703993084/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine
    Australia 29 05 2009 CSL Limited ASX CSL Australia s leading biopharmaceutical company announced today that its US subsidiary CSL Biotherapies Inc has signed a contract with the U S Department of Health and Human Services HHS to provide Novel A H1N1 influenza vaccine antigen in bulk form The vaccine will be manufactured at CSL s facility in Parkville Victoria and will support the HHS pre pandemic influenza preparation efforts

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1242703933086/prdetail.htm (2014-01-05)
    Open archived version from archive